Tetrapyrroles and derivatives
Abcam Bisindolylmaleimide II, PKC inhibitor, 5MG
MW 438.5 Da, Purity >97%. Potent, selective ATP-competitive PKC inhibitor (IC₅₀ values are 0.01, 0.75 and 2 μM for PKC, phosphorylase kinase and PKA respectively). Potent noncompetitive nAChR antagonist (IC₅₀ = 0.03 μM, catecholamine secretion in nicotine-stimulated PC-12 cells). Shows more potent antinicotinic effects than Bisindolylmaleimide IV (ab144208) and V (ab144205). Induces apoptosis and shows antiproliferative effects.
The product is subject to the following: Abcam Restricted Use Statement
Abcam (±)-SKF38393 hydrochloride, D1-like dopamine receptor agonist, 100MG
MW 291.77 Da, Purity >98%. D1-like dopamine receptor agonist. pKi values are 9 (D1), 6.8 (D2), 5.3 (D3), 6.0 (D4) and 9.3 (D5). Ki values are 151 and 2364 nM for D1-like and D2-like dopamine receptors, respectively. Centrally active upon systemic administration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam x estospongin C, IP3 receptor antagonist, 50UG
MW 446.72 g/mol, Purity >90%. Potent, selective, reversible IP₃ receptor antagonist (IC₅₀ = 350 nM). Inhibits IP₃-mediated Ca²+ release from ER and SR. 30-Fold selectivity over ryanodine receptor. Inhibits voltage-dependent Ca²+ and K+ channels at higher concentrations. Cell-permeable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam (R)-CPP, NMDA antagonist, 10MG
MW 252.2 Da. Highly potent, competitive NMDA antagonist; more active enantiomer of (RS)-CPP (ab120160). (Ki values are 0.04, 0.3, 0.6 and 2.0 μM at NR1/NR2A, NR1/NR2B, NR1/NR2C and NR1/NR2D, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam L-745870 trihydrochloride, brain penetrant D4 antagonist, 10MG
MW 436.21 g/mol, Purity >99%. Highly potent and selective D₄ antagonist (Ki values are 0.43, 2300 and 960 nM at D₄, D₃ and D₂, respectively). Brain permeable. Inhibits cell death and shows neuroprotective effects.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 505124, ALK5 inhibitor, 10MG
MW 335.4 Da, Purity >98%. Potent, reversible, competitive ALK5 inhibitor (IC₅₀ values are 47 and 129 nM for ALK5 and ALK4 respectively). Inhibits ALK7 but not ALK1, 2, 3, or 6. Shows antifibrotic effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 203580, p38 MAPK inhibitor, 500UG
MW 377.4 Da, Purity >99%. SB 203580, p38 MAPK inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
![Medchemexpress LLC Zinc, [29H,31H-phthalocyaninato(2-)-κN29,κN30,κN31,κN32]-, (SP-4-1)- | 14320-04-8 | 98.0% | 577.90 | 10 G](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000385853-logo.png-250.jpg){kind=logo}
Medchemexpress LLC Zinc, [29H,31H-phthalocyaninato(2-)-κN29,κN30,κN31,κN32]-, (SP-4-1)- | 14320-04-8 | 98.0% | 577.90 | 10 G
Zinc, [29H,31H-phthalocyaninato(2-)-κN29,κN30,κN31,κN32]-, (SP-4-1)- | 14320-04-8 | 98.0% | 577.90 | 10 G
Abcam E x endin (9-39) amide, GLP-1 receptor antagonist, 1MG
MW 3369.8 Da, Purity >98%. Exendin (9-39) amide, GLP-1 receptor antagonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam EMD 386088 hydrochloride, 5-HT6 agonist, 50MG
MW 283.2 Da, Purity >98%. Potent 5-HT6 agonist (IC50 = 7.4 nM in 3H-LSD binding and EC50 = 1.0 nM in a functional cAMP assay). Selective over other 5-HT receptors (IC50 values are 110 (5-HT1D), 180 (5-HT1B), 240 (5-HT2A), 450 (5-HT2C), 620 (5-HT4), 660 (5-HT1A ) and 3000 nM (5-HT7)). Shows moderate affinity at 5-HT3 receptors (IC50 = 34 nM). Impairs memory *in vivo*.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 505124, ALK5 inhibitor, 5MG
MW 335.4 Da, Purity >98%. Potent, reversible, competitive ALK5 inhibitor (IC₅₀ values are 47 and 129 nM for ALK5 and ALK4 respectively). Inhibits ALK7 but not ALK1, 2, 3, or 6. Shows antifibrotic effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB-3CT, MMP-2 and MMP-9 inhibitor, 1MG
MW 306.4 Da, Purity >98%. Potent, competitive and non-selective MMP-2 and MMP-9 inhibitor (Ki values are 13.9 and 600 nM for MMP-2 and MMP-9 respectively). Does not alter the activity of MMP-1, MMP-3 or MMP-7 (Ki values are 206 (MMP-1), 15 (MMP-3) and 96 (MMP-7) μM). Neuroprotective and blood-brain barrier permeable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Edaravone (MCI-186), antio x idant, 50MG
MW 174.2 Da, Purity >99%. Free radical scavenger and potent antioxidant. Inhibits production of reactive oxygen species, apoptosis and the lipoxygenase system.
The product is subject to the following: Abcam Restricted Use Statement
Abcam PD 168077 maleate, D4 agonist, 10MG
MW 450.49 g/mol, Purity >98%. Potent, selective D₄ dopamine receptor agonist. Displays >400-fold selectivity over D₂ and >300-fold selectivity over D₃ subtypes (Ki values are 11.9, 2540, and 1050 nM for D₄, D₃, and D₂ receptors, respectively). Reverses object recognition deficits.
The product is subject to the following: Abcam Restricted Use Statement
